Manufactured by AbbVie, Produodopa is a subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe ...

Levodopa-induced dyskinesia (LID) is a common complication after dopamine-replacement therapy in Parkinson's disease. The neural mechanisms underlying LID are far from clear, although significant ...

US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to .Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the ...

At 28 years old, Dr. Soania Mathur was building her medical practice and expecting her first child. Then she was diagnosed ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on TRVI stock, giving a Buy rating yesterday. Thomas Smith has given ...

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) ...

Among the lixisenatide and placebo groups, 100% and 97% were receiving levodopa, 45% and 41% were receiving monoamine oxidase B inhibitors, and 69% and 78% were receiving dopamine agonist, ...

Q1 2024 Earnings Call Transcript May 8, 2024 ACADIA Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge ...

Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6 million. Total revenues excluding ...

During the quarter, Knight in-licensed IPX203 for Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa ("CD/LD") extended-release capsules designed for the treatment of ...

Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, ...